3[1]Okun E,Butler WT. Ophthalmologic complications of cryptococcal meningitis.Arch Ophthalmol, 1964,71:52
4[2]Michael C,Bach MD,Philip W,et al.Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension.Neurosurgery, 1997,41:1280
5[3]Rex JH,Larsen RA,Dismukes WE,et al.Catastrophic visual loss due to cryptococcus neoformans meningitis.Medicine,1993,72:207
6Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Clinical Infect Dis 2000; 30:710-718.
4Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull, 2005, 72(l): 99-118.
5Bicanic T, Mazoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV- associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin infect Dis, 2009, 49(5): 702-709.
6Holmes CB, Losina E, Walensky RP, et al. Review of human im- munodeficiency virus type 1-related opportunistic infections in Sub- Saharan Africa. Clin Infect Dis, 2003, 36(5): 652-662.
7Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in anti-fungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimi-crob Agents Chem- other, 2001, 45(11): 3065-3069.
8Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis, 2000, 30(4): 710-718.
9Baddley JW and Pappas PG. Antigungal combination therapy: clini- cal potential. Drugs, 2005, 65(11): 1461-1480.
